Episode
Unlocking Pharma’s Data Bottleneck: Justin Byers, Founder & CEO of Axio BioPharma
- Podcast
- The Brand Called You
- Published
- Jul 9, 2026
- Duration seconds
- 1464
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-brand-called-you-1170976/episodes/unlocking-pharma-s-data-bottleneck-justin-byers-founder-ceo-of-axio-biopharma/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-brand-called-you-1170976/unlocking-pharma-s-data-bottleneck-justin-byers-founder-ceo-of-axio-biopharma.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The Brand Called You, we welcome Justin Byers, Founder & CEO of Axio BioPharma, for an insightful discussion on transforming the biopharma industry through data coordination and infrastructure innovation. The conversation focused on lessons from Justin’s experience at leading pharmaceutical companies, the challenges of fragmented process data, and why connecting siloed systems—not the science itself—is the industry's greatest hurdle. The discussion explored how a unique combination of biotechnology and cybersecurity expertise shaped Axio BioPharma’s federated, vendor-neutral architecture. One key concept was the importance of providing a coordination layer that enables AI models to reach their full potential by connecting and structuring high-quality data across multiple platforms. A key theme that emerged was the importance of neutrality and trust when handling sensitive pharmaceutical data, and why large manufacturers cannot easily serve as neutral coordination layers. The conversation also explored the technical challenges of standardizing data across disparate systems, the parallels between the future of biomanufacturing and financial networks, and the value of firsthand operational experience. Tune in to discover how Justin and Axio BioPharma are bridging operational realities with digital innovation to accelerate breakthroughs in pharmaceutical manufacturing and AI-driven process development.